Rubicon Genomics, Inc.

Rubicon Genomics is a leader in the development of improved technologies for detecting the pattern of DNA methylation in cancer cells. Rubicon has developed a superior test to non-invasively diagnose cancer and other diseases using its proprietary MethylPlex™ technology to amplify the exceedingly small amounts of abnormally-methylated DNA that are released by diseased tissue into serum and urine. MethylPlex has proven sensitivity and simplicity advantages over current competitive tests for methylated DNA tumor markers. The increased technical sensitivity will enable earlier, more reliable non-invasive detection of disease as well as allow for more methylation markers to be assayed in a single test, thus increasing both diagnostic sensitivity and specificity. The increased simplicity of MethylPlex enables inexpensive, robust tests utilizing currently existing diagnostic platforms. Achievement of these sensitivity and simplicity milestones make MethylPlex the first cancer diagnostic tool to meet the performance and cost criteria required for population screening

Contact Details: 4370 Varsity Drive, Suite G Ann Arbor Michigan 48108 United States of America Tel: 734.677.6210 Fax: 734.477.9902 Email: thompson@rubicongenomics.com WWW: www.rubicongenomics.com/

Loading...

Press Releases on Rubicon Genomics, Inc.:
ZyGEM Corp. Signs Agreement to Incorporate Its Breakthrough DNA Extraction Technology Into Rubicon's Research and Diagnostic Products	28th May, 2009	ZyGEM Corp. Ltd.	-Latest in Series of Global Distribution Agreements to Make ZyGEM's Lower-Cost, Rapid and Easy-to-Use DNA Extraction Kits Available to Researchers Everywhere- -ZyGEM Also Announces Issuance of U
Rubicon Genomics Announces a Licensing Agreement With Abbott to Develop and Commercialize DNA Methylation Cancer Tests	12th January, 2009	Rubicon Genomics, Inc.	ANN ARBOR, Mich., Jan. 12 /PRNewswire/ -- Rubicon Genomics today announced a licensing agreement with Abbott, which marks the achievement of significant milestones within their on-going Research and
Rubicon Provides Genome Amplification for the Cancer Genome Atlas Project	13th October, 2008	Rubicon Genomics, Inc.	ANN ARBOR, Mich., Oct. 13 /PRNewswire/ -- Rubicon Genomics, Inc. today announced an agreement with SAIC-Frederick to amplify DNA samples for The Cancer Atlas Genome Project. Rubicon Genomics
Rubicon Genomics, Inc. today announced the launch of their GenomePlex™	1st January, 1970	Rubicon	Rubicon Genomics, Inc. today announced the launch of their GenomePlex™ whole genome amplification (WGA) point of use kit Ann Arbor, MI, November 10, 2003—Rubicon Genomics, Inc. today announced

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 275 times since April 2007, the link to the organisation's website has been followed 43 times

Search for more companies in Ann Arbor

Search for more companies in Michigan

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Rubicon Genomics, Inc.